

NEWS RELEASE

Teijin Regenet, TOHO HOLDINGS and ITOCHU Corp. Enter into Business Alliance Aimed at Building Novel Regenerative Medicine Ecosystem

Industry leaders will collaborate to support early and efficient launch of promising regenerative medicine seed ideas by biotech venture companies.

Tokyo, July 10, 2025 --- [Teijin Limited](#) announced today that its subsidiary, Teijin Regenet Co., Ltd., has entered into a business alliance with [TOHO HOLDINGS CO., LTD.](#) and [ITOCHU Corporation](#) to build a regenerative medicine ecosystem that helps biotech venture companies in Japan launch new products more smoothly and rapidly. The three companies are pooling their strengths to provide a single source for services from development to marketing of regenerative medical products. Their vision is to facilitate delivery of new and innovative treatments to patients.


Currently, each biotech venture company engaged in developing regenerative medical products individually arranges for facilities and equipment, procures materials and handles logistics necessary for cell culture. This complex process spans each phase of the product launch, including research and development, manufacturing, distribution and sales. Drawbacks include inefficiency, unnecessary labor and high costs. This system is one factor causing biotech venture companies with limited funds to abandon development before their product is launched.

To address this challenge, Teijin Regenet, TOHO HOLDINGS and ITOCHU Corp. are combining their diverse strengths in areas such as manufacturing process development, logistics and material procurement. Through this regenerative medicine ecosystem, they will provide a “one-stop shop” of high-quality services to biotech venture companies and others developing regenerative medical products. This ecosystem will reduce financial and operational burdens and support the efficient and early launch of regenerative medical products.

The roles of each company are described below and illustrated in the figure.

- Teijin Regenet: Cell culture and research support in the research phase, support for manufacturing process development and production of investigational drugs in the development phase, and production of final products in the manufacturing and marketing phases.
- TOHO HOLDINGS: Logistics in each phase and project evaluation in the research phase.

- ITOCHU Corporation: Procurement of materials in the research and development phases, and development of materials in the research phase.



Regenerative Medicine Ecosystem

Building the regenerative medicine ecosystem will begin this summer with a briefing for companies developing regenerative medical products regarding their issues and needs. In addition, the three companies will begin offering development support services, including joint use of cell culture facilities at Teijin Regenet's Kashiwanoha facility. In the future, they will explore other forms of support that leverage the strengths of each company.

About Teijin Regenet

Established in 2023, Teijin Regenet is a contract development and manufacturing organization (CDMO) for regenerative medical products. It operates the Kashiwanoha facility for contract development and cell processing, and the Iwakuni factory for contract manufacturing.

Teijin Regenet aims to achieve the Teijin Group's sales target of 20 billion yen for its regenerative medicine business by fiscal year 2030. To meet expanding demand for contract development services both domestically and internationally, the company will continue to invest in facilities and human resources.

About TOHO HOLDINGS

This corporate group is active in the medical, nursing and healthcare fields, where it is engaged in manufacturing, wholesaling, dispensing and sales of pharmaceuticals. TOHO HOLDINGS also offers development and provision of customer support systems under the

corporate slogan, “Total Commitment to Good Health”. TOHO HOLDINGS proactively promotes initiatives for regional medical collaboration, nursing and home care.

About ITOCHU Corporation

ITOCHU leverages its global network as a trading company and its business development expertise to invest in regenerative medicine venture companies. It procures and supplies materials necessary for the development and manufacture of regenerative medical products.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Teijin is committed to its purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its long-term vision, “To be a company that supports the society of the future.” Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.

Press Contact

Corporate Communication Department

Teijin Limited

pr@teijin.co.jp